Gastrointestinal Stromal Tumour (GIST) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

LB1709 Prevalence of skin cancer screening visits in medicare data: A retrospective cohort study
Skin cancer screening is a common reason for dermatology visits, though it is not guideline-supported in the US for the general population. There are no estimates of how much of US dermatologists ’ time is spent on skin cancer screening. We aimed to investigate the proportion of dermatology visits that include skin cancer screening over time. We used a de-identified, random sample of 4,999,999 Medicare beneficiaries aged ≥65 years from 2009-2018. We included all encounters with dermatolo gists and excluded procedure-only visits. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - August 21, 2023 Category: Dermatology Authors: M.K. Nowakowska, Y. Li, C. Mohr, B. Smith, L. Ferris, M. Wehner Source Type: research

Clinical-radiomics-based treatment decision support for KIT Exon 11 deletion in gastrointestinal stromal tumors: a multi-institutional retrospective study
ConclusionThe radiomics models based on enhanced CT for predicting KIT exon 11 deletion mutations have good diagnostic performance. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - August 14, 2023 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 15, Pages 4081: Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
litano Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Surgical treatment is recommended for the majority of localised GIST, while systemic treatment is the cornerstone of management for metastatic or unresectable disease. While a three-year regimen of imatinib is the standard of care in the adjuvant setting, there is no precise recommendation for the duration of neoadjuvant treatment, where imatinib is usually given between 4 and 12 months. Continuous treatment with imatinib at a dose of 400 mg once per day is recommended for most patients with unresectabl...
Source: Cancers - August 13, 2023 Category: Cancer & Oncology Authors: Marin Gol čić Robin L. Jones Paul Huang Andrea Napolitano Tags: Review Source Type: research

Electronic patient-reported outcome (ePRO) application for patients with prostate cancer
ConclusionThe developed application can help to accelerate communication with the specialists. It can improve quality of care, reduce unnecessary treatment visits and side effects, and improve timely data collection for a variety of research purposes. However, further research on the cost-effectiveness and usefulness of the collected data is recommended. (Source: PLoS One)
Source: PLoS One - August 11, 2023 Category: Biomedical Science Authors: Majid Mohseni Source Type: research

Cancers, Vol. 15, Pages 3879: KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
u Adjuvant imatinib improves the recurrence-free survival and overall survival (OS) of patients with gastrointestinal stromal tumors (GISTs) who have a high risk of recurrence after surgery and is now considered standard treatment. Yet, OS benefit has been demonstrated in only one randomized study, the Scandinavian Sarcoma Group XVIII/AIO trial, where patients with high-risk GISTs were allocated to either 1 year or 3 years of adjuvant imatinib. SSGXVIII/AIO is also the only randomized trial in which adjuvant imatinib duration exceeding 2 years was evaluated. In this trial, the 3-year treatment led to a 45% reduction in...
Source: Cancers - July 30, 2023 Category: Cancer & Oncology Authors: Heikki Joensuu Tags: Review Source Type: research

Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era
CONCLUSIONS: We developed a novel, next-generation genomic risk stratification model for primary gastric and small bowel GISTs, complementing traditional clinicopathologic models. Future independent validation of our model in external cohorts is essential.PMID:37477937 | DOI:10.1158/1078-0432.CCR-23-1184 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 21, 2023 Category: Cancer & Oncology Authors: Josephine Kam Tai K Dermawan Ciara Kelly Zhidong Gao Shaleigh Smith Bhumika Jadeja Samuel Singer William D Tap Ping Chi Cristina R Antonescu Source Type: research

Raf kinase inhibitor protein combined with phosphorylated extracellular signal-regulated kinase offers valuable prognosis in gastrointestinal stromal tumor
CONCLUSION: Our experimental results showed that the expression of RKIP and P-ERK proteins in GIST was associated with tumor size, NIH 2008 staging, and tumor invasion, and P-ERK expression was also related to mitotic count. The expression of the two proteins had a certain negative correlation. The combined expression of RKIP and P-ERK proteins can serve as an independent risk factor for predicting the prognosis of GIST patients. The new risk assessment model incorporating RKIP and P-ERK has superior evaluation efficacy and is worth further practical application to validate.PMID:37475847 | PMC:PMC10354573 | DOI:10.3748/wjg...
Source: World Journal of Gastroenterology : WJG - July 21, 2023 Category: Gastroenterology Authors: Wen-Zhi Qu Luan Wang Juan-Juan Chen Yang Wang Source Type: research

Raf kinase inhibitor protein combined with phosphorylated extracellular signal-regulated kinase offers valuable prognosis in gastrointestinal stromal tumor
CONCLUSION: Our experimental results showed that the expression of RKIP and P-ERK proteins in GIST was associated with tumor size, NIH 2008 staging, and tumor invasion, and P-ERK expression was also related to mitotic count. The expression of the two proteins had a certain negative correlation. The combined expression of RKIP and P-ERK proteins can serve as an independent risk factor for predicting the prognosis of GIST patients. The new risk assessment model incorporating RKIP and P-ERK has superior evaluation efficacy and is worth further practical application to validate.PMID:37475847 | PMC:PMC10354573 | DOI:10.3748/wjg...
Source: World Journal of Gastroenterology - July 21, 2023 Category: Gastroenterology Authors: Wen-Zhi Qu Luan Wang Juan-Juan Chen Yang Wang Source Type: research